The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus
Comparison in people · 1999
- What was studied
- 61 people with SLE; four groups of 15, 15, 15 and 16; eight-week comparison
- Main finding
- A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.
Antibodies and lupus activity · Reported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scores · No group-level values or effect sizes in abstract
Reported findings and study design
A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.
Four groups of 15, 15, 15 and 16 patients; background prednisolone with different adjuncts; eight-week assessment.
Dose, route and schedule
Bemitil: 500–750 mg/day orally for eight weeks, studied alone or with cyclophosphamide. Combination-arm results do not establish Bemitil’s independent effect.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Antibodies and lupus activity | Reported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scores | No group-level values or effect sizes in abstract |
| Group sizes | 15, 15, 15 and 16 patients | The count spans multiple groups. |
| Bemitil exposure | 500–750 mg/day orally | Eight-week comparison; the indexed background-drug dose units need original verification |
Several concurrent-treatment arms prevent interpreting this as Bemitil monotherapy. Unverified background-drug units are not reproduced as dosing instructions.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- SLE is a different disease; these findings do not establish efficacy in MS.
- Allocation and blinding cannot be established from the abstract; concomitant therapy complicates attribution.
- The 1997 dissertation and 2000 patent appear to describe the same research program.
Related publications may describe some of the same participants or experiments.
Source details
Indexed English abstract
The summary reflects the results reported in the cited source.
Abstract reviewed
Sources checked
Citation
T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova. The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751